Apart from FGF-23, some traditional prognostic factors could also predict MACCE risk in ULMCAD patients receiving CABG, including age ≥65 years, diabetes, previous stroke, LVEF <50%, and higher disease extent, which was in line with a previous study (3). This evidence concerns the gene FGF23 and diabetes mellitus.